The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis.

The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis.

Publication date: Jan 19, 2024

The influence of inhaled corticosteroids (ICS) on COVID-19 outcomes remains uncertain. To address this, we conducted a systematic review and meta-analysis, analyzing 30 studies, to investigate the impact of ICS on patients with COVID-19. Our study focused on various outcomes, including mortality risk, hospitalization, admission to the intensive care unit (ICU), mechanical ventilation (MV) utilization, and length of hospital stay. Additionally, we conducted a subgroup analysis to assess the effect of ICS on patients with chronic obstructive pulmonary disease (COPD) and asthma. Our findings suggest that the prior use of ICS did not lead to significant differences in mortality risk, ICU admission, hospitalization, or MV utilization between individuals who had used ICS previously and those who had not. However, in the subgroup analysis of patients with COPD, prior ICS use was associated with a lower risk of mortality compared to non-users (OR, 0. 95; 95% CI, 0. 90-1. 00). Overall, while the use of ICS did not significantly affect COVID-19 outcomes in general, it may have beneficial effects specifically for patients with COPD. Nevertheless, more research is needed to establish a definitive conclusion on the role of ICS in COVID-19 treatment. PROSPERO registration number: CRD42021279429.

Open Access PDF

Concepts Keywords
Corticosteroids Admission
Crd42021279429 Analysis
Hospitalization Conducted
Obstructive Copd
Pulmonary Corticosteroids


Type Source Name
disease MESH COVID-19
disease MESH chronic obstructive pulmonary disease
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK Pirenzepine
drug DRUGBANK Coenzyme M
drug DRUGBANK Indoleacetic acid
disease MESH syndrome
disease IDO history
disease IDO process
pathway REACTOME Reproduction
disease VO organization
disease MESH breakthrough infections
disease MESH chronic kidney disease
disease MESH hypertension
disease MESH pneumonia
disease MESH infections
disease IDO symptom
disease IDO infection
disease VO protocol
drug DRUGBANK Budesonide
drug DRUGBANK Fluticasone
drug DRUGBANK Ciclesonide
drug DRUGBANK Methionine
disease MESH respiratory diseases
disease VO population
drug DRUGBANK Angiotensin II
drug DRUGBANK Amlodipine

Original Article

(Visited 1 times, 1 visits today)